

In the Claims

Amend claim 1, as follows:

1. (Currently amended) A method of treating a corticosteroid-responsive disease of the ~~upper, or~~ lower airway passages or of the lungs in ~~patients afflicted with said disease, which comprises~~ comprising administering ~~once a day once daily to the surfaces of~~ said passages or lungs ~~of said patients a substantially non-systematically bioavailable amount of aerosolized particles from a dry powder inhaler about 400 micrograms~~ of mometasone furoate ~~effective for treating said disease.~~

Cancel claims 2-29.

Add claims 30-45, as follows:

30. (New) The method of claim 1, wherein the mometasone furoate is administered as anhydrous mometasone furoate.

31. (New) The method of claim 1, wherein the mometasone furoate is administered as mometasone furoate monohydrate.

32. (New) The method of claim 1, wherein the mometasone furoate is administered together with a bronchodilator.

33. (New) The method of claim 1, wherein the disease is at least one member selected from asthma, chronic obstructive pulmonary disease, granulomatous diseases, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and bronchopulmonary dysplasia.

34. (New) The method of claim 1, wherein there are administered 400 micrograms of mometasone furoate by two inhalations of about 200 micrograms of mometasone furoate.

35. The method of claim 34, wherein the disease comprises asthma.

36. (New) The method of claim 1, wherein there are administered 400 micrograms of mometasone furoate by one inhalation of about 400 micrograms of mometasone furoate.

37. (New) The method of claim 36, wherein the disease comprises asthma.

38. (New) A method of treating a corticosteroid-responsive disease of the lower airway passages or of the lungs, comprising administering once daily to said passages or lungs from a dry powder inhaler about 800 micrograms of mometasone furoate.

39. (New) The method of claim 38, wherein the mometasone furoate is administered as anhydrous mometasone furoate.

40. (New) The method of claim 38, wherein the mometasone furoate is administered as mometasone furoate monohydrate.

41. (New) The method of claim 38, wherein the disease is at least one member selected from asthma, chronic obstructive pulmonary disease, granulomatous diseases, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and bronchopulmonary dysplasia.

42. (New) The method of claim 38, wherein there are administered 800 micrograms of mometasone furoate by two inhalations of about 400 micrograms of mometasone furoate.

43. (New) The method of claim 42, wherein the disease comprises chronic obstructive pulmonary disease.

44. (New) The method of claim 38, wherein there are administered 800 micrograms of mometasone furoate by four inhalations of about 200 micrograms of mometasone furoate.

45. (New) The method of claim 44, wherein the disease comprises chronic obstructive pulmonary disease.